Superworth

Quest Diagnostics DGX

Medical - Diagnostics & Research, Healthcare
$250.20
−0.24%
Market cap
$27.5B
PE
24.9×
10y median 19.3×
Forward PE
n/m
not a meaningful number
Price to sales
2.3×
EV/EBIT
19.0×
Revenue, 12 months
$11.8B
+9% on a year ago
Net margin
9.5%
Free cash flow yield
5.0%

Quest Diagnostics trades at 24.9× trailing earnings, pricier than 98% of the last ten years. Revenue was $11.8B over the last twelve months, up 9% on a year earlier with a 10% net margin.

Charts

Financials

Income statement for DGX, by quarter
Income statementQ4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26
$2.3B−2%$2.4B+2%$2.4B+3%$2.5B+8%$2.6B+15%$2.7B+12%$2.8B+15%$2.8B+13%$2.8B+7%$2.9B+9%$3B+10%$3.1B+10%
Cost of revenue$1.6B−2%$1.6B+2%$1.6B+3%$1.7B+9%$1.8B+14%$1.8B+12%$1.8B+14%$1.9B+11%$1.9B+8%$2B+9%$2B+11%$2.1B+10%
Gross profit$736M−3%$771M+0%$804M+2%$811M+8%$858M+17%$863M+12%$943M+17%$949M+17%$910M+6%$942M+9%$1B+9%$1B+10%
SG&A$407M−28%$440M+0%$416M+0%$448M+18%$466M+15%$476M+8%$486M+17%$501M+12%$504M+8%$504M+6%$529M+9%$523M+4%
$267M+98%$300M−2%$355M+2%$330M−4%$361M+35%$346M+15%$438M+23%$386M+17%$386M+7%$399M+15%$459M+5%$479M+24%
Interest expense$46M+28%$43M+16%$44M+13%$49M+23%$65M+41%$67M+56%$67M+52%$66M+35%$64M−2%$63M−6%$63M−6%$61M−8%
Pre-tax income$237M+117%$266M−4%$314M−1%$296M−1%$299M+26%$276M+4%$384M+22%$328M+11%$330M+10%$334M+21%$412M+7%$416M+27%
$40M$66M+2%$74M−1%$65M−4%$68M+70%$59M−11%$97M+31%$77M+19%$81M+19%$74M+25%$88M−9%$99M+29%
Net income$192M+90%$194M−4%$229M−3%$226M+0%$222M+16%$220M+13%$282M+23%$245M+8%$245M+10%$252M+15%$320M+14%$312M+27%
$1.75+99%$1.72−3%$2.03−1%$1.99+2%$1.91+9%$1.94+13%$2.47+22%$2.16+9%$2.17+14%$2.24+16%$2.84+15%$2.78+29%
110M−4%112M−1%112M−2%113M−1%116M+6%113M+1%113M+1%113M+0%113M−3%112M−1%112M−1%112M−1%

Gross profit: 74 periods, Q2 FY08 to Q3 FY26: not printed by the filing, worked out from its own lines.

EPS, diluted: Q4 FY08: quarter's net income to common over its shares, to the cent, the shares from counts implied by EPS, near the year's EPS less the nine months'. 5 periods, Q4 FY21 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 16 periods, Q4 FY10 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Estimates

Next earnings report: .

QuarterRevenueRangeEPSRangeAnalysts
Q4 FY26$3B$3B to $3.1B$2.68$2.66 to $2.7010
Q1 FY27$3B$3B to $3B$2.70$2.59 to $2.848
Q2 FY27$3.2B$3.2B to $3.2B$3.08$3.05 to $3.124
Q3 FY27$3.2B$3.2B to $3.3B$3.14$3.11 to $3.183
Q4 FY27$3.2B$3.2B to $3.2B$2.94$2.91 to $2.984
Q1 FY28$3.1B$3.1B to $3.2B$3.03$3.00 to $3.074
Q2 FY28$3.3B$3.3B to $3.3B$3.36$3.32 to $3.405
Q3 FY28$3.4B$3.3B to $3.4B$3.40$3.36 to $3.454

Peers

Companies in Medical - Diagnostics & Research nearest Quest Diagnostics' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
DGXQuest Diagnostics$27.5B24.9×19.3×n/m2.3×+9%9.5%
LHLabcorp$28.9B29.4×19.5×18.8×2.0×+6%7.0%
MTDMettler-Toledo International$34.2B38.4×36.6×34.6×8.3×+7%21.9%
ILMNIllumina$35.7B44.0×51.3×41.5×8.0×+5%18.4%
MEDPMedpace$18.1B38.0×34.5×n/m6.5×+25%17.7%
IQVIQVIA$42.5B32.0×34.8×19.0×2.5×+8%8.1%
WATWaters$46.4B118×29.2×30.4×10.0×+52%3.6%
RVTYRevvity$16.9B72.2×35.1×n/m5.8×+4%8.2%
AAgilent Technologies$49.6B34.5×33.2×26.8×6.7×+9%19.5%
IDXXIDEXX Laboratories$52.1B46.5×54.9×42.4×11.4×+13%25.0%
BIOBio-Rad Laboratories$9.8B44.4×30.9×n/m3.8×+1%8.6%
Peer median$35B41.2×34.7×30.4×6.6×+8%13.1%

More on Quest Diagnostics

Each number over time

Where it ranks

Its groups

About

Industry
Medical - Diagnostics & Research
Sector
Healthcare

Valuation data, not investment advice. Prices as of .